165 reports of this reaction
1.3% of all ENFORTUMAB VEDOTIN reports
#19 most reported adverse reaction
STEVENS JOHNSON SYNDROME is the #19 most commonly reported adverse reaction for ENFORTUMAB VEDOTIN, manufactured by SEAGEN INC.. There are 165 FDA adverse event reports linking ENFORTUMAB VEDOTIN to STEVENS JOHNSON SYNDROME. This represents approximately 1.3% of all 12,251 adverse event reports for this drug.
Patients taking ENFORTUMAB VEDOTIN who experience stevens johnson syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
STEVENS JOHNSON SYNDROME is a less commonly reported adverse event for ENFORTUMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to stevens johnson syndrome, the following adverse reactions have been reported for ENFORTUMAB VEDOTIN:
The following drugs have also been linked to stevens johnson syndrome in FDA adverse event reports:
STEVENS JOHNSON SYNDROME has been reported as an adverse event in 165 FDA reports for ENFORTUMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
STEVENS JOHNSON SYNDROME accounts for approximately 1.3% of all adverse event reports for ENFORTUMAB VEDOTIN, making it a notable side effect.
If you experience stevens johnson syndrome while taking ENFORTUMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.